ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
Coffee with America: Dr. William Audeh for Agendia Breast Cancer Subtyping
Discover why understanding the specific characteristics of breast cancer is crucial for developing personalized treatment strategies that can significantly improve outcomes. Dr. William Audeh, a leading medical oncologist specializing in breast cancer and Agendia Read More
Genomic Testing Transforms Breast Cancer Care and Treatment Success
In an insightful interview with Dr. William Audeh, MD, MS, Chief Medical Officer at Agendia, featured in ONCOLife, we explore the pioneering strides in genomic testing within breast cancer treatment. Dr. Audeh, shares his Read More
Recognizing Common Breast Cancer Symptoms & the Importance of Early Detection
Breast cancer is the most common cancer among women, with about 1 in 8 women being diagnosed in their lifetime.[1] It also accounts for nearly 30% of all new female cancer diagnoses each year, with Read More
Faith Over Fear, My Life Matters (Winter 2023-2024)
A journey to inclusive breast cancer care through faith, science, and personalized testing.
Read the ArticleNews
Media Releases
Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN
Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer
Read MoreAgendia Presents Data from FLEX Study at Miami Breast 2024
Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens
Read MoreAgendia Reports First Patient Enrolled in DEBRA Trial Using MammaPrint
MammaPrint 70-gene signature to aid in evaluation of de-escalation of radiation therapy in Stage I, Hormone Sensitive, HER2-Negative breast cancer
Read MoreAgendia® Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michigan’s Dr. Erin Cobain
SWOG S2206 will use MammaPrint® breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.
Read More